Cognitive Screening in Lung Cancer Patients
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
This study aims to investigate the occurrence of cancer and adjuvant therapy-related cognitive impairment in patients with both NSCLC and SCLC. The primary endpoint measure will be the presence of cognitive impairment during the first year after enrollment through the administration of a comprehensive neuropsychological assessment.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:
• Small-cell and non-small-cell lung cancer (stage I, II, III, IV)
• Age ≥ 18 years
• Patients able to speak and read the local language(s) fluently
• Acceptance and signature of informed consent
Locations
Other Locations
Italy
Istituto Europeo di Oncologia
RECRUITING
Milan
Contact Information
Primary
Gabriella Pravettoni
gabriella.pravettoni@ieo.it
+39025489731
Backup
Lorenzo Conti
+390257489731
Time Frame
Start Date: 2024-01-10
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 200
Treatments
patients diagnosed with lung cancer
patients diagnosed with lung cancer (both SCLC and NSCLC)
Related Therapeutic Areas
Sponsors
Leads: European Institute of Oncology